Oscient Pharmaceuticals Corporation

Schering Corporation

Bristol-myers Squibb Compnay

Genome Therapeutics Corporation

Merck Sharp + Dohme Corp.

Jason Samuel Simon

Randall D Little

Kristina Allen

Sunil D Pandit

Tim Keith

Paul Van Eerdewegh

Richard Giulio Del Mastro

Josée Dupuis

Nicholas J Murgolo

Fang Liang Zhang

Lin Luo

Ying Jiang

Josèe Dupuis

Richard Del Mastro

Petra B Ross-Macdonald

Ping Qiu

Kevin Shianna

Alexander J Thompson

Thomas Urban

Arthur Bertelsen

Jos&egrave;e Dupuis

Jacques Fellay

Jos&eacute;e Dupuis

Dongliang Ge

David B Goldstein

John G McHutchison

Dongliang De

Robert Orville Ii Ralston

This disclosure provides methods for treating a subject afflicted with a tumor derived from a renal cell carcinoma. The methods comprise administering a first dose to a subject of an anti-PD-1 antibody or antigen-binding portion thereof and/or an anti-PD-L1 antibody or antigen-binding portion thereof, and administering a second dose to the subject, wherein the subject exhibited differential expression in one or more biomarker genes, e.g., CTLA-4, TIGIT, and/or PD-L2, following administration of the first dose.

Treatment of renal cell carcinoma

This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.

Nucleotide and amino acid sequences relating to respiratory diseases and obesity

The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-&#x3b1;). These IFN-&#x3b1; response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-&#x3b1; pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-&#x3b1;, and in methods for selecting the most appropriate therapy for such patients.

Genetic markers associated with interferon-alpha response

The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.

Antibodies and functional fragments thereof that specifically bind an RF-amide peptide or a precursor thereof

This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.

Human genes relating to respiratory diseases and obesity

G-protein coupled receptor ligands and methods

This invention relates to isolated nucleic acids comprising genes of human chromosome 20p13-p12 and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.

Human gene relating to respiratory diseases and obesity

Growing community of inventors

Westfield, NJ, United States of America

Jason Samuel Simon